WO2006108686A3 - Bnp agonists - Google Patents

Bnp agonists Download PDF

Info

Publication number
WO2006108686A3
WO2006108686A3 PCT/EP2006/003473 EP2006003473W WO2006108686A3 WO 2006108686 A3 WO2006108686 A3 WO 2006108686A3 EP 2006003473 W EP2006003473 W EP 2006003473W WO 2006108686 A3 WO2006108686 A3 WO 2006108686A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
xaa1
xaa3
xaa2
alkyl
Prior art date
Application number
PCT/EP2006/003473
Other languages
French (fr)
Other versions
WO2006108686A2 (en
Inventor
Anne-Marie Lambeir
Inger Brandt
Simon Scharpe
Meester Ingrid De
Original Assignee
Aic
Anne-Marie Lambeir
Inger Brandt
Simon Scharpe
Meester Ingrid De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic, Anne-Marie Lambeir, Inger Brandt, Simon Scharpe, Meester Ingrid De filed Critical Aic
Publication of WO2006108686A2 publication Critical patent/WO2006108686A2/en
Publication of WO2006108686A3 publication Critical patent/WO2006108686A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present invention relates to dipeptidyl peptidase resistant BNP agonists, their synthesis and therapeutic applications thereof. In particular the present invention relates to compounds of formula (I): R-Xaa1-Xaa2-Xaa3-Pep-OH ; wherein R is selected from the group comprising hydrogen, acetyl, formyl, or alkyl, wherein Xaa1 is an amino-acid selected from serine, alanine, threonine or asparagine, Xaa2 is a L-amino acid or a D-amino acid, different from L-proline, L-alanine, L-glycine or L-serine, optionally substituted by at least one substituent selected from alkyl, aryl or acyl, and Xaa3 is a L-amino acid or a D-amino acid, optionally substituted by at least one substituent selected from alkyl, acetyl, or aryl, wherein Xaa1, Xaa2, Xaa3 are linked to each other by peptide bonds or pseudo-peptide bonds, and wherein Pep is a peptide sequence comprising not more than 29 amino acid residues said sequence comprising a disulfide linked ring structure said ring comprising between 12 and 20 amino acids, wherein the disulfide bond is formed by two cysteines.
PCT/EP2006/003473 2005-04-14 2006-04-14 Bnp agonists WO2006108686A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05447080.2 2005-04-14
EP05447080 2005-04-14

Publications (2)

Publication Number Publication Date
WO2006108686A2 WO2006108686A2 (en) 2006-10-19
WO2006108686A3 true WO2006108686A3 (en) 2006-12-21

Family

ID=36954070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/003473 WO2006108686A2 (en) 2005-04-14 2006-04-14 Bnp agonists

Country Status (1)

Country Link
WO (1) WO2006108686A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043526A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
CN112094338B (en) * 2019-05-14 2022-03-25 深圳市亚辉龙生物科技股份有限公司 Amino-terminal brain natriuretic peptide precursor polypeptide and conjugated protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AHLUWALIA A ET AL: "Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 3, March 2005 (2005-03-01), pages 162 - 167, XP004771640, ISSN: 0165-6147 *
AMININASAB M ET AL: "Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 557, no. 1-3, 16 January 2004 (2004-01-16), pages 104 - 108, XP004485668, ISSN: 0014-5793 *
BIDZSERANOVA A ET AL: "Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats", NEUROPEPTIDES, XX, XX, vol. 23, no. 2, October 1992 (1992-10-01), pages 61 - 65, XP002390351, ISSN: 0143-4179 *
DESCHENES J ET AL: "Development of a selective peptide antagonist for the human natriuretic peptide receptor-B", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 26, no. 3, March 2005 (2005-03-01), pages 517 - 524, XP004989568, ISSN: 0196-9781 *
SCHOENFELD J R ET AL: "Mutations in B-type natriuretic peptide mediating receptor-A selectivity", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 414, no. 2, 8 September 1997 (1997-09-08), pages 263 - 267, XP004366327, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2006108686A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
IN2014CN02050A (en)
PE20091753A1 (en) PEPTIDE ANTAGONIST CONJUGATES ANALOGUE TO PUMP
CA2651990C (en) Improved antimicrobial peptides
UA103154C2 (en) Hla-a*-1101-restricted wt1 peptide and pharmaceutical composition comprising thereof
SK2052001A3 (en) Peptide analogues, process for their preparation, pharmaceutical composition containing same, their use and intermediates
HU205141B (en) Process for producing peptide boronic acid derivatives inhibiting trypsin-like protease, as well as pharmaceutical compositions comprising such compounds as active ingredient
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
JP2002530430A (en) Pharmaceutical composition for inhibiting hepatitis C virus NS3 protease
ATE482978T1 (en) MIMETIC CD4 PEPTIDES AND THEIR USES
NZ610732A (en) Novel angiotensin type 2 (at2) receptor agonists and uses thereof
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
ATE280827T1 (en) PENAEIDINE: ANTIMICROBIAL PEPTIDES FROM CRUSTACEANS
WO2006108686A3 (en) Bnp agonists
EP0696199A4 (en) Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
AU2008339610B2 (en) Methods of peptide modification
CA2883531A1 (en) Stable peptide-based furin inhibitors
Debowski et al. Hybrid analogues of SFTI‐1 modified in P1 position by β‐and γ‐amino acids and N‐substituted β‐alanines
Roumelioti et al. Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3, 5 side-chain bridges: role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists
GB0717526D0 (en) Improvements in or relating to compositions for the treatment or prophylaxis of viral infections
US5776903A (en) Peptide derivatives usable as zinc endopeptidase 24-15 inhibitors
CA2720778C (en) Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopeptidases
EP1730174A4 (en) Peptide carrier for drug delivery
KR900004762A (en) New peptidase inhibitor
TW201730203A (en) Method for preparation of RADA-16
HK1147210A1 (en) Anti-hypertensive agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06753391

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6753391

Country of ref document: EP